CoChat

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice

Open access
Nguyen, Thiquynhnga, Wen, Song, Gong, Min, Yuan, Xinlu, Xu, Dongxiang, Wang, Chaoxun, Jin, Jianlan, Zhou, Ligang · 2020 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index; 3 of the 46 sources its claims cite were checked for support.

Abstract

PURPOSE: This study investigates the possible effect and central mechanism of novel antidiabetic medication sodium glucose transporter-2 (SGLT-2i) on the cardiovascular activity. MATERIAL AND METHODS: Thirty-four normal male C57BL/6 mice were randomly assigned to 2 groups to receive single Dapagliflozin (1.52mg/kg) dose via intragastric gavage or a comparable dose of saline. Glycemic level (BG), blood pressure (BP) and heart rate (HR) were measured 2 hours after administration of the respective treatments. Immunohistochemical tests were performed to determine the effect of SGLT-2i on neural localization of SGLT-2 and c-Fos, a neural activator. The distributional relationships of SGLT-2 and c-Fos were examined by immunofluorescence. RESULTS: Administration of SGLT-2i significantly decreased BP but did not affect the HR. There was no difference in BG between the two groups. Results showed that SGLT-2 was localized to specific regions involved in autonomic control. Expression of c-Fos was significantly higher in major critical nuclei in the aforementioned regions in groups treated with Dapagliflozin. CONCLUSION: This study demonstrates that SGLT-2 is expressed in CNS tissues involved in autonomic control and possibly influence cardiovascular function. Dapagliflozin influences central autonomic activity via unidentified pathways by inhibiting central or peripheral SGLT-2. These results provide a new concept that sympathetic inhibition by SGLT-2i can be mediated by central autonomic system, a mechanism that explains how SGLT-2i improves the cardiovascular function.

Overview

CoChat Summary

TL;DR

In normal male C57BL/6 mice, a single intragastric dapagliflozin dose (1.52 mg/kg) lowered systolic and diastolic blood pressure at 2 h without significantly changing heart rate or blood glucose, while increasing c-Fos in autonomic nuclei. The authors localize SGLT-2 in hypothalamus, amygdala, periaqueductal gray, and nucleus of the solitary tract, and propose central SGLT-2 inhibition activates autonomic circuits, especially PVN, to regulate cardiovascular activity.

Key findings

  • Dapagliflozin did not significantly change blood glucose at 2 h versus saline (9.5 ± 0.163 vs 9.6 ± 0.163 mmol/l, P > 0.05); values at 1 h and 2 h were lower in dapagliflozin but not statistically significant (1 h: 8.9 ± 0.331 vs 9.1 ± 0.331 mmol/l; 2 h: 7.9 ± 0.229 vs 8.5 ± 0.229 mmol/l; P > 0.05).
  • At 2 h after gavage, systolic BP was 111.265 ± 3.964 mmHg in dapagliflozin vs 128.932 mmHg in control, and diastolic BP was 88.289 ± 3.971 vs 105.236 ± 1.756 mmHg (both P < 0.05); heart rate did not differ significantly (389.147 ± 16.018 vs 435.403 ± 6.188, P > 0.05).
  • SGLT-2 was abundantly expressed in brain regions related to autonomic control, including hypothalamus, amygdala, periaqueductal gray (PAG), and nucleus of the solitary tract (NTS).
  • c-Fos expression was significantly higher after dapagliflozin in many autonomic nuclei, including PVN (78.000 ± 3.873 vs 30.000 ± 4.235), NTS (95.500 ± 3.704 vs 50.000 ± 3.661), PAG (115.833 ± 3.229 vs 71.000 ± 4.844), and LC (74.667 ± 5.451 vs 34.500 ± 5.359; all P < 0.05).

Methods

  • Thirty-four normal male C57BL/6 mice were randomized to dapagliflozin (1.52 mg/kg, n = 17) or saline (n = 17) by intragastric gavage; blood glucose was measured before, every 15 min for the first hour, and 2 h after administration. The paper also reports 14 male mice randomized for BP and HR measurement at 0, 1, and 2 h using a non-invasive volume-pressure-sensing monitor.
  • Brains were processed for immunohistochemistry for SGLT-2 and c-Fos, Nissl staining, and dual immunofluorescence; Fos-immunoreactivity was quantified blinded based on the Allen mouse brain atlas.
  • Statistical analysis used two-way ANOVA with Sidak multiple comparison tests for Fos-IR, repeated-measures ANOVA with Sidak tests for blood glucose, and repeated-measures ANOVA with Tukey tests for BP and HR; P ≤ 0.05 was considered significant.

Limitations

  • Stated: the authors did not explore the dynamics of SGLT-2i in the brain due to technical limitations, and they note that more precise techniques such as radiography or fluorescent labeling are needed in future studies.
  • Stated: urine volume was not monitored, and the authors note that other neural pathways may exist through which dapagliflozin activates neurons in autonomic areas.
  • Evident from the text: the study used normal mice rather than a T2DM model, tested only an acute single dose with a 2-h observation window, and did not directly establish whether the cardiovascular effects are caused by central versus peripheral SGLT-2 inhibition.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/dmso.s258593

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (A) Analysis of blood glucose in mice 2 h after administration of SGLT-2i (Dapagliflozin). There was no difference in blood glucose across groups. n = 34, RM-ANOVA, Sidak multiple comparison test. (B) Comparison of systolic pressure between control and SGLT-2i before and at 2 h after administration of treatments, n = 14, mean ± SEM. *P < 0.05 vs control. ns: P > 0.05 vs control. RM ANOVA, Tukey multiple comparison test. (C) Comparison of diastolic pressure between control and SGLT-2i before and at 2 h after administration of treatments, n = 14, mean ± SEM. *P < 0.05 vs control. ns: P > 0.05 vs control. RM ANOVA, Tukey multiple comparison test. (D) Comparison of heart rate between control and SGLT-2i before and at 2 h after administration of treatments, n = 14, mean ± SEM. ns: P > 0.05 vs control. RM ANOVA, Tukey multiple comparison test.
Figure 1 (A) Analysis of blood glucose in mice 2 h after administration of SGLT-2i (Dapagliflozin). There was no difference in blood glucose across groups. n = 34, RM-ANOVA, Sidak multiple comparison test. (B) Comparison of systolic pressure between control and SGLT-2i before and at 2 h after administration of treatments, n = 14, mean ± SEM. *P < 0.05 vs control. ns: P > 0.05 vs control. RM ANOVA, Tukey multiple comparison test. (C) Comparison of diastolic pressure between control and SGLT-2i before and at 2 h after administration of treatments, n = 14, mean ± SEM. *P < 0.05 vs control. ns: P > 0.05 vs control. RM ANOVA, Tukey multiple comparison test. (D) Comparison of heart rate between control and SGLT-2i before and at 2 h after administration of treatments, n = 14, mean ± SEM. ns: P > 0.05 vs control. RM ANOVA, Tukey multiple comparison test.CC BY-NC · PubMed Central
Figure 2 Grayscale contrast showing expression of SGLT-2 in Telencephalon (A and B); Diencephalon (C and D); Midbrain and Brainstem (E and F). Abbreviations: AOM, medial anterior olfactory region; AOL, anterior olfactory nucleus, lateral part; AOD, anterior olfactory nucleus, dorsal part; AOVP, anterior olfactory nucleus, ventroposterior part; DTT, dorsal tenia tecta layer; E/OV, olfactory ventricle (olfactory part of lateral ventricle); AOP, anterior olfactory nucleus, posterior part; aca, anterior commissure, anterior part; PrL, prelimbic cortex; fmi, forceps minor of the corpus callosum; CPu, caudate putamen (striatum); Nv, navicular nucleus of the basal forebrain; DTT, dorsal tenia tecta; DP, dorsal peduncular cortex; Cg2, cingulate cortex, area 2; LSI, lateral septal nucleus, intermediate part; LSV, lateral septal nucleus, ventral part; LSD, lateral septal nucleus, dorsal part; VDB, nucleus of the vertical limb of the diagonal band; CC, corpus callosum; LSD, lateral septal nucleus, dorsal part; MnPO, median preoptic nucleus; BNST, bed nucleus of the stria terminalis; ac, anterior commissure; LPO, lateral preoptic area; MPA, medial preoptic area; MPO, medial preoptic nucleus; PVA, paraventricular thalamic nucleus, anterior part; PVN, paraventricular hypothalamic nucleus; CM, central medial thalamic nucleus; AM, anteromedial thalamic nucleus; Re, reuniens thalamic nucleus; LH, lateral hypothalamus; RCh, retrochiasmatic area; CA3, field CA3 of the hippocampus; PVA, paraventricular thalamic nucleus, anterior part; PVP, paraventricular thalamic nucleus, posterior part; PV, paraventricular thalamic nucleus; IAM, interanteromedial thalamic nucleus; Re, reuniens thalamus nucleus; PH, posterior hypothalamic nucleus; AHC, anterior hypothalamic area, central part; DMD, dorsomedial hypothalamic nucleus, dorsal part; DM, dorsomedial hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus; VMHVL, ventromedial hypothalamic nucleus, ventrolateral part; Arc, arcuate hypothalamic nucleus; ME, median eminence; ML, medial mammillary nucleus, lateral part; VTM, ventral tuberomammillary nucleus; p1PAG, p1 periaqueductal gray; PrC, precommissural nucleus; PAG, periaqueductal gray; Aq, aqueduct; Pn, pontine nuclei; DCIC, dorsal cortex of the inferior colliculus; DLL, dorsal nucleus of the lateral leminiscus; DRD, dorsal raphe nucleus, dorsal part; PTg, pedunculopontine tegmental nucleus; LPB, lateral parabrachial nucleus; DTgP, dorsal tegmental nucleus, pericentral part; DTgC, dorsal tegmental nucleus, central part; CG, central gray; LC, locus coerules; PDTg, posterodorsal tgmental nucleus; PO, periolivary nucleus; py, pyramidal tract; 4V, 4th ventricle; solitary tract nucleus; Rt, reticular nucleus; AP, area postrema.
Figure 2 Grayscale contrast showing expression of SGLT-2 in Telencephalon (A and B); Diencephalon (C and D); Midbrain and Brainstem (E and F). Abbreviations: AOM, medial anterior olfactory region; AOL, anterior olfactory nucleus, lateral part; AOD, anterior olfactory nucleus, dorsal part; AOVP, anterior olfactory nucleus, ventroposterior part; DTT, dorsal tenia tecta layer; E/OV, olfactory ventricle (olfactory part of lateral ventricle); AOP, anterior olfactory nucleus, posterior part; aca, anterior commissure, anterior part; PrL, prelimbic cortex; fmi, forceps minor of the corpus callosum; CPu, caudate putamen (striatum); Nv, navicular nucleus of the basal forebrain; DTT, dorsal tenia tecta; DP, dorsal peduncular cortex; Cg2, cingulate cortex, area 2; LSI, lateral septal nucleus, intermediate part; LSV, lateral septal nucleus, ventral part; LSD, lateral septal nucleus, dorsal part; VDB, nucleus of the vertical limb of the diagonal band; CC, corpus callosum; LSD, lateral septal nucleus, dorsal part; MnPO, median preoptic nucleus; BNST, bed nucleus of the stria terminalis; ac, anterior commissure; LPO, lateral preoptic area; MPA, medial preoptic area; MPO, medial preoptic nucleus; PVA, paraventricular thalamic nucleus, anterior part; PVN, paraventricular hypothalamic nucleus; CM, central medial thalamic nucleus; AM, anteromedial thalamic nucleus; Re, reuniens thalamic nucleus; LH, lateral hypothalamus; RCh, retrochiasmatic area; CA3, field CA3 of the hippocampus; PVA, paraventricular thalamic nucleus, anterior part; PVP, paraventricular thalamic nucleus, posterior part; PV, paraventricular thalamic nucleus; IAM, interanteromedial thalamic nucleus; Re, reuniens thalamus nucleus; PH, posterior hypothalamic nucleus; AHC, anterior hypothalamic area, central part; DMD, dorsomedial hypothalamic nucleus, dorsal part; DM, dorsomedial hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus; VMHVL, ventromedial hypothalamic nucleus, ventrolateral part; Arc, arcuate hypothalamic nucleus; ME, median eminence; ML, medial mammillary nucleus, lateral part; VTM, ventral tuberomammillary nucleus; p1PAG, p1 periaqueductal gray; PrC, precommissural nucleus; PAG, periaqueductal gray; Aq, aqueduct; Pn, pontine nuclei; DCIC, dorsal cortex of the inferior colliculus; DLL, dorsal nucleus of the lateral leminiscus; DRD, dorsal raphe nucleus, dorsal part; PTg, pedunculopontine tegmental nucleus; LPB, lateral parabrachial nucleus; DTgP, dorsal tegmental nucleus, pericentral part; DTgC, dorsal tegmental nucleus, central part; CG, central gray; LC, locus coerules; PDTg, posterodorsal tgmental nucleus; PO, periolivary nucleus; py, pyramidal tract; 4V, 4th ventricle; solitary tract nucleus; Rt, reticular nucleus; AP, area postrema.CC BY-NC · PubMed Central
Figure 3 Comparison of FOS-IR for nuclei between control and SGLT-2i in telencephalon (A); amygdalar nuclei and hippocampus (B); thalamus (C); hypothalamus (D); midbrain (E); brainstem (F), n = 12, mean ± SEM. *P < 0.05 vs control; ns: no significance; Two-way ANOVA, Sidak multiple comparison test. Abbreviations: BNST, bed nucleus of stria terminalis; MnPO, median preoptic nucleus; LPO, lateral preoptic area; MPO, medial preoptic nucleus; MPA, medial preoptic area; MS, medial septum; Me, medial amygdala nucleus; Ce, central amygdala nucleus; BMA, basomedial amygdala nucleus; BLA, basolateral amygdala nucleus; Pirl, piriform cortex; CA3, field CA3 of the hippocampus; PVA, paraventricular nucleus of thalamus; CM, central medial thalamic nucleus; Rh, rhomboid thalamic nucleus; Re, reuniens thalamic nucleus; IAM, interanteromedial thalamic nucleus; PVN, paraventricular nucleus of hypothalamus; VMH, ventromedial hypothalamus; LH, lateral hypothalamic area; ARC, arcuate nucleus; AHC, anterior hypothalamic nucleus; SC, superior colliculus; PAG, periaqueductal gray; DR, dorsal raphe nucleus; PTg, pedunculopontine tegmental nucleus; VTA, ventral tegmental area; Pn, potine nucleus; AP, area postrema; Sol/NTS, nucleus of solitary tract; Py, pyramidal tract; LC, locus coeruleus; CG, central gray; PO, periolivary nucleus; LPB, lateral parabrachial nucleus; Rt, reticular nucleus.
Figure 3 Comparison of FOS-IR for nuclei between control and SGLT-2i in telencephalon (A); amygdalar nuclei and hippocampus (B); thalamus (C); hypothalamus (D); midbrain (E); brainstem (F), n = 12, mean ± SEM. *P < 0.05 vs control; ns: no significance; Two-way ANOVA, Sidak multiple comparison test. Abbreviations: BNST, bed nucleus of stria terminalis; MnPO, median preoptic nucleus; LPO, lateral preoptic area; MPO, medial preoptic nucleus; MPA, medial preoptic area; MS, medial septum; Me, medial amygdala nucleus; Ce, central amygdala nucleus; BMA, basomedial amygdala nucleus; BLA, basolateral amygdala nucleus; Pirl, piriform cortex; CA3, field CA3 of the hippocampus; PVA, paraventricular nucleus of thalamus; CM, central medial thalamic nucleus; Rh, rhomboid thalamic nucleus; Re, reuniens thalamic nucleus; IAM, interanteromedial thalamic nucleus; PVN, paraventricular nucleus of hypothalamus; VMH, ventromedial hypothalamus; LH, lateral hypothalamic area; ARC, arcuate nucleus; AHC, anterior hypothalamic nucleus; SC, superior colliculus; PAG, periaqueductal gray; DR, dorsal raphe nucleus; PTg, pedunculopontine tegmental nucleus; VTA, ventral tegmental area; Pn, potine nucleus; AP, area postrema; Sol/NTS, nucleus of solitary tract; Py, pyramidal tract; LC, locus coeruleus; CG, central gray; PO, periolivary nucleus; LPB, lateral parabrachial nucleus; Rt, reticular nucleus.CC BY-NC · PubMed Central
Figure 4 Analysis of c-Fos expression between SGLT-2i (A, B, C) and control group (D, E, F) in MnPO, PVA, and PVN (A); Superior colliculus, PAG, and LC (B); NTS, CA3, and amygdalar nuclei (C); Scale bar: 100μm. Abbreviations: MnPO, median preoptic nucleus; ac, anterior commissure; PVA, paraventricular thalamic nucleus; D3V, dorsal 3rd ventricle; PVN, paraventricular hypothalamic nucleus; 3V, 3rd ventricle; Aq, aqueduct; PAG, periaqueductal gray; LC, locus coeruleus; 4V, 4th ventricle; NTS, nucleus of solitary tract; AP, area postrema; CC, central canal; CA3, the field CA3 of hippocampus; Me, medial amygdala nucleus; Ce, central amygdala nucleus; BMA, basomedial amygdala nucleus; BLA, basolateral amygdala nucleus; Pirl, piriform cortex.
Figure 4 Analysis of c-Fos expression between SGLT-2i (A, B, C) and control group (D, E, F) in MnPO, PVA, and PVN (A); Superior colliculus, PAG, and LC (B); NTS, CA3, and amygdalar nuclei (C); Scale bar: 100μm. Abbreviations: MnPO, median preoptic nucleus; ac, anterior commissure; PVA, paraventricular thalamic nucleus; D3V, dorsal 3rd ventricle; PVN, paraventricular hypothalamic nucleus; 3V, 3rd ventricle; Aq, aqueduct; PAG, periaqueductal gray; LC, locus coeruleus; 4V, 4th ventricle; NTS, nucleus of solitary tract; AP, area postrema; CC, central canal; CA3, the field CA3 of hippocampus; Me, medial amygdala nucleus; Ce, central amygdala nucleus; BMA, basomedial amygdala nucleus; BLA, basolateral amygdala nucleus; Pirl, piriform cortex.CC BY-NC · PubMed Central
Figure 5 Continued.
Figure 5 Continued.CC BY-NC · PubMed Central
Figure 5 Continued.
Figure 5 Continued.CC BY-NC · PubMed Central
Figure 5 (A) c-Fos expression is upregulated in SGLT-2i group (A, B, C, D) vs control group (E, F, G, H) as determined by immunofluorescence assay in MnPO (A); PVA (B); PVN (C); SC (D); PAG (E); LC (F); NTS (G); CA3 (H); Me (I); Red: Alexa Fluor-594, staining showing c-Fos expression in nucleus of neurons; Green: Alexa Fluor-488, staining showing SGLT-2 expression surround nucleus of neurons; Scale bar: 100μm. Magnification: A and E=5X; B, C, D and F, G, H=20X. Abbreviations: MnPO, median preoptic nucleus; ac, anterior commissure; PVA, paraventricular thalamic nucleus; D3V, dorsal 3rd ventricle; PVN, paraventricular hypothalamic nucleus; 3rdV, 3rd ventricle; SC, superior colliculus; Aq, aqueduct; PAG, periaqueductal gray; Aq, aqueduct; LC, locus coeruleus; 4V, 4th ventricle; AP, area postrema; NTS, nucleus of solitary tract; CC, central canal; D3V, dorsal 3rd ventricle; CA3, the field CA3 of hippocampus; Me, medial amygdala nucleus; Ce, central amygdala nucleus; BMA, basomedial amygdala nucleus; BLA, basolateral amygdala nucleus; Pirl, piriform cortex.
Figure 5 (A) c-Fos expression is upregulated in SGLT-2i group (A, B, C, D) vs control group (E, F, G, H) as determined by immunofluorescence assay in MnPO (A); PVA (B); PVN (C); SC (D); PAG (E); LC (F); NTS (G); CA3 (H); Me (I); Red: Alexa Fluor-594, staining showing c-Fos expression in nucleus of neurons; Green: Alexa Fluor-488, staining showing SGLT-2 expression surround nucleus of neurons; Scale bar: 100μm. Magnification: A and E=5X; B, C, D and F, G, H=20X. Abbreviations: MnPO, median preoptic nucleus; ac, anterior commissure; PVA, paraventricular thalamic nucleus; D3V, dorsal 3rd ventricle; PVN, paraventricular hypothalamic nucleus; 3rdV, 3rd ventricle; SC, superior colliculus; Aq, aqueduct; PAG, periaqueductal gray; Aq, aqueduct; LC, locus coeruleus; 4V, 4th ventricle; AP, area postrema; NTS, nucleus of solitary tract; CC, central canal; D3V, dorsal 3rd ventricle; CA3, the field CA3 of hippocampus; Me, medial amygdala nucleus; Ce, central amygdala nucleus; BMA, basomedial amygdala nucleus; BLA, basolateral amygdala nucleus; Pirl, piriform cortex.CC BY-NC · PubMed Central
Figure 6 Comparison of the known peripheral pathway (black full line) with central pathway proposed in this study (blue dotted line) through which SGLT-2i regulates cardiovascular processes. The list of mechanisms through which SGLT-2 inhibitors improve cardiac function both via peripheral and central pathways. SGLT-2 inhibitors inhibit peripheral reabsorption of sodium and glucose in proximal convoluted tubules (upper left corner) leading to natriuresis and glucosuria. Natriuresis can deplete the plasma volume and increase tubuloglomerular feedback. Reduced glucose reabsorption may result in a decrease in body weight, glyco-toxicity and inflammation accompanied by uricosuria. In terms of central mechanism, SGLT-2 inhibitors may act on cardiovascular regulation related nuclei, such as PVN, NTS, PAG and other nuclei. SGLT-2 inhibitors may eventually act on RVLM to influence the sympathetic flow to IML with sympathetic preganglionic neurons. Eventually, this promotes the parasympathetic nervous activity thereby decreases blood pressure and heart rate. Abbreviations: PVN, paraventricular nucleus of hypothalamus; NTS, nucleus of solitary tract; PAG, periaqueductal gray; RVLM, rostral ventrolateral medulla; IML, intermediolateral nucleus of spinal cord; BP, blood pressure.
Figure 6 Comparison of the known peripheral pathway (black full line) with central pathway proposed in this study (blue dotted line) through which SGLT-2i regulates cardiovascular processes. The list of mechanisms through which SGLT-2 inhibitors improve cardiac function both via peripheral and central pathways. SGLT-2 inhibitors inhibit peripheral reabsorption of sodium and glucose in proximal convoluted tubules (upper left corner) leading to natriuresis and glucosuria. Natriuresis can deplete the plasma volume and increase tubuloglomerular feedback. Reduced glucose reabsorption may result in a decrease in body weight, glyco-toxicity and inflammation accompanied by uricosuria. In terms of central mechanism, SGLT-2 inhibitors may act on cardiovascular regulation related nuclei, such as PVN, NTS, PAG and other nuclei. SGLT-2 inhibitors may eventually act on RVLM to influence the sympathetic flow to IML with sympathetic preganglionic neurons. Eventually, this promotes the parasympathetic nervous activity thereby decreases blood pressure and heart rate. Abbreviations: PVN, paraventricular nucleus of hypothalamus; NTS, nucleus of solitary tract; PAG, periaqueductal gray; RVLM, rostral ventrolateral medulla; IML, intermediolateral nucleus of spinal cord; BP, blood pressure.CC BY-NC · PubMed Central

Verification

Claims the paper makes

3 Valid · 1 Not valid · 22 Not checked · 53 Own results and interpretations

40 more claims

Create a free account to see all 79 claims and to verify the 43 references still open.

See all claims — free account
  • It may state two separate claims as one. 19
  • The quote only partly states this claim. 3
  • Probably not a substantial claim. 18

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 97

Metadata

Authors
Nguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L.
Affiliations
Fudan University (CN)
Corresponding author
Zhou, Ligang
Venue
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Published
2020-08
Volume
Volume 13
Pages
2781-2799
ISSN
1178-7007 (ISSN-L)
OpenAlex
W3046924930
Cited by
97
References
66
Citations by year
2026: 10 · 2025: 27 · 2024: 18 · 2023: 21 · 2022: 11 · 2021: 8 · 2020: 2
FWCI
7.92
Type
journal article
Language
en
Open access
Locations
  • Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • Natural Science Foundation of Shanghai (ZHYY-ZXYJHZX-2-201712, PWR12014-06, PWYgy-2018-08, 21675034, 19ZR1447500, 81370932)
  • National Natural Science Foundation of China (PWYgy-2018-08, 81370932, PWR12014-06, 19ZR1447500, PWZzk2017-03, ZHYY-ZXYJHZX-2-201712, 21675034)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
Keywords
dapagliflozin, SGLT2 inhibitors, central nervous system, autonomic nervous system, c-fos, blood pressure, heart rate, GLUT2, cardiovascular effects, antidiabetic drugs, sympathoinhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.